Improve Human Health By Developing Potent Therapeutics Against Medically Validated, Yet Undruggable Targets
Our platform, BEYOND, leverages our proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing us to discover new therapeutics to targets previously believed undruggable.
MARCEL FRENKEL, PhD
Co-founder and CEO
Marcel has gone from soup to nuts in inhibitor design, having helped develop in silico methods and algorithms, while also experimentally validating inhibitors to currently undruggable targets such as KRas. He has also worked on predicting resistance mutations and mechanisms, and on therapeutic antibody development. Fun fact: he is a Division I Fencing National Champion for the University of Notre Dame and has represented his native country Brazil in multiple world championships.
Jane is a MacArthur (Genius) Fellow and Member of the National Academies of Sciences and Medicine. She is world-renowned for the development of the ribbon diagram representation of proteins and all-atom contact mapping.
Recently she was awarded the Alexander Hollaender Award (2019), the top award in biophysics, by the National Academy of Sciences.